Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression

[1]  A. Atala.  Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer. , 2017, The Journal of urology.

[2]  F. Claessens,et al.  The role of TET-mediated DNA hydroxymethylation in prostate cancer , 2017, Molecular and Cellular Endocrinology.

[3]  T. H. van der Kwast,et al.  Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance , 2017, The Journal of urology.

[4]  Ji-Hak Jeong,et al.  A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance. , 2017, Molecular cell.

[5]  J. Sung,et al.  Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. , 2016, European urology.

[6]  S. Chanock,et al.  TET2 binds the androgen receptor and loss is associated with prostate cancer , 2016, Oncogene.

[7]  N. Maitland,et al.  The molecular and cellular origin of human prostate cancer. , 2016, Biochimica et biophysica acta.

[8]  K. Helin,et al.  Role of TET enzymes in DNA methylation, development, and cancer , 2016, Genes & development.

[9]  Gary D Bader,et al.  Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis , 2016, Clinical Epigenetics.

[10]  Jana Jeschke,et al.  Portraits of TET-mediated DNA hydroxymethylation in cancer. , 2016, Current opinion in genetics & development.

[11]  D. Smiraglia,et al.  Hormone stimulation of androgen receptor mediates dynamic changes in DNA methylation patterns at regulatory elements , 2015, Oncotarget.

[12]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[13]  K. D. Sørensen,et al.  High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer , 2015, Clinical Epigenetics.

[14]  Y. Homma,et al.  TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression , 2015, Nature Communications.

[15]  M. Gu,et al.  NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis. , 2015, International journal of clinical and experimental medicine.

[16]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[17]  A. Rao,et al.  Connections between TET proteins and aberrant DNA modification in cancer. , 2014, Trends in genetics : TIG.

[18]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[19]  Jin-cheng Pan,et al.  Association between RASSF1A Promoter Methylation and Prostate Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.

[20]  Karin M. Fredrikson,et al.  Somatic Alterations Contributing to Metastasis of a Castration‐Resistant Prostate Cancer , 2013, Human mutation.

[21]  William A. Pastor,et al.  TETonic shift: biological roles of TET proteins in DNA demethylation and transcription , 2013, Nature Reviews Molecular Cell Biology.

[22]  Z. Ling,et al.  Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation , 2013, Oncogene.

[23]  R. Eeles,et al.  The role of genetic markers in the management of prostate cancer. , 2012, European urology.

[24]  T. Triche,et al.  Transcriptome-Wide Detection of Differentially Expressed Coding and Non-Coding Transcripts and Their Clinical Significance in Prostate Cancer , 2012, Journal of oncology.

[25]  T. H. van der Kwast,et al.  Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer , 2012, Epigenetics.

[26]  Y. Lussier,et al.  Deregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression , 2012, Clinical Cancer Research.

[27]  T. H. van der Kwast,et al.  Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression , 2011, International journal of cancer.

[28]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[29]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[30]  David S. Lapointe,et al.  ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data , 2010, BMC Bioinformatics.

[31]  Cory Y. McLean,et al.  GREAT improves functional interpretation of cis-regulatory regions , 2010, Nature Biotechnology.

[32]  J. Trachtenberg,et al.  DNA methylation of HOXD3 as a marker of prostate cancer progression , 2010, Laboratory Investigation.

[33]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[34]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[35]  M. Hoque,et al.  A Quantitative Promoter Methylation Profile of Prostate Cancer , 2004, Clinical Cancer Research.

[36]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[37]  D. Hollywood,et al.  Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. , 2004, Endocrine-related cancer.

[38]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Olivier Cussenot,et al.  Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  T. Shinka,et al.  Down-regulation of drs mRNA in human prostate carcinomas. , 2003, Human pathology.

[41]  O. Cussenot,et al.  Quantification of expression of netrins, slits and their receptors in human prostate tumors , 2003, International journal of cancer.

[42]  Rui Henrique,et al.  Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. , 2002, Urology.

[43]  T. Stamey,et al.  Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. , 2001, The Journal of urology.

[44]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  W. Isaacs,et al.  CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.